ulmonary emphysema is common, chronic, progressively disabling, and eventually fatal. The disease is caused by cigarette smoking in 80% to 90% of the cases. The pathologic process destroys and hyperinfl ates alveoli, reduces lung elastic recoil, and impairs gas exchange. The pathophysiology is compounded by compromised ventilation as the hyperinfl ated lungs are entrapped in a nonpliable chest cage and cannot expand adequately during inspiration. The most debilitating clinical manifestations of emphysema are dyspnea and reduced exercise tolerance. In the advanced phases, the patient is breathless during ordinary activities and eventually even at rest. At this stage palliation becomes a more relevant treatment goal than increased longevity. 
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Observational and randomized studies provide convincing evidence that lung volume reduction surgery (LVRS) improves symptoms, lung function, exercise tolerance, and life span in welldefi ned subsets of patients with emphysema. Yet, in the face of an estimated 3 million patients with emphysema in the United States, , 15 LVRS operations are performed monthly under the aegis of Medicare, in part because of misleading reporting in lay and medical publications suggesting that the operation is associated with prohibitive risks and offers minimal benefi ts. Thus, a treatment with proven potential for palliating and prolonging life may be underutilized. In an attempt to lower risks and cost, several bronchoscopic strategies (bronchoscopic emphysema treatment [BET]) to reduce lung volume have been introduced. The following three methods have been tested in some depth: (1) unidirectional valves that allow exit but bar entry of gas to collapse targeted hyperinfl ated portions of the lung and reduce overall volume; (2) biologic lung volume reduction (BioLVR) that involves intrabronchial administration of a biocompatible complex to collapse, infl ame, scar, and shrink the targeted emphysematous lung; and (3) airway bypass tract (ABT) or creation of stented nonanatomic pathways between hyperinfl ated pulmonary parenchyma and bronchial tree to decompress and reduce the volume of oversized lung. The results of pilot and randomized pivotal clinical trials suggest that the bronchoscopic strategies are associated with lower mortality and morbidity but are also less effi cient than LVRS. Most bronchoscopic approaches improve quality-of-life measures without supportive physiologic or exercise tolerance benefi ts. Although there is promise of limited therapeutic infl uence, the available information is not suffi cient to recommend use of bronchoscopic strategies for treating emphysema.
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Medical treatment of emphysema offers modest symptomatic relief but does not halt disease progression. Several surgical therapies were proposed during the last century but none proved useful until Brantigan, in 1956 , resected the most diseased portions of the emphysematous lungs (lung volume reduction surgery, LVRS) in an attempt to diminish the size mismatch between lung and chest cage and to improve the mechanics of the remaining organ. 1 The operative mortality was 16%, but many who survived surgery experienced subjective improvement. Unfortunately, corroborative physiologic measurements were not obtained and LVRS was not accepted as effective therapy.
Using modern surgical technology combined with careful patient selection, Cooper et al 2 reintroduced LVRS in 1995 with reduced operative mortality (4.8%). The improvements in symptoms were corroborated with pulmonary function, exercise tolerance, and quality of life (QOL) measures. The gratifying results were reproduced by others and a wave of enthusiastic LVRS use followed. [3] [4] [5] A metaanalysis of six small randomized clinical trials (RCTs), incorporating 306 patients, also showed favorable results ( Table 1 ) . 9 In 1996, the Centers for Medicare and Medicaid Services and the National Institutes of Health cosponsored a 17-center nationwide RCT, the National Emphysema Treatment Trial (NETT). From 3,997 patients screened, 1,218 were enrolled. An interim analysis identifi ed 140 patients as "high risk for LVRS" and enrollment from this category was halted. 10 The outcomes from the remaining 1,078 individuals confi rmed that in selected cohorts LVRS confers durable symptomatic, physiologic, and survival benefi ts with a 5.5% mortality, . 50% morbidity, and substantial fi nancial outlay ( Table 1 ) . 11 In an attempt to reduce the risks and cost associated with LVRS a search for nonsurgical approaches ensued. The purpose of this article is to present an updated analysis on surgery or resection for lung cancer were deemed prohibitive but who tolerated the indicated surgery when it was combined with LVRS. 14, 15 Following publication of NETT's results, Centers for Medicare and Medicaid Services extended LVRS coverage for patients belonging to NETT outcome categories 1, 2, and 3, but not category 4 ( Table 3 ) . 16 Despite the strong evidence of the palliative and survival benefi ts from LVRS, only 258 operations were performed between January 2004 and September 2005 under the aegis of Medicare. 17 The surprisingly low use may be due in part to a prevailing impression generated in part by misleading reporting in effect that LVRS is mini mally effective with unacceptably high morbidity and mortality. [18] [19] [20] 
BET
The LVRS experience established that lung volume reduction is on sound clinical and physiologic grounds. 21 Several nonoperative bronchoscopic approaches have been developed in an attempt to reap the benefi ts of LVRS but at lower risks and costs. Data sufficient for analysis are available from the following strategies:
1. Deployment of unidirectional valves into the airways to collapse the targeted lung parenchyma and decreased its volume. subjects and almost identical to the 250-patient heterogeneous LVRS observational experience of Ciccone et al ( Fig 1 ) . 6 NETT's upper-lobe LVRS cohort also exhibited better 5-year survival than patients having lung transplants for COPD. 8 Communications in the literature also describe patients with severely compromised pulmonary function from emphysema in whom the risks of cardiac mal Vapor Ablation (Update Inc.; Seattle, WA) and nitinol self-actuating reduction coils (PneumRx Inc.; Mountain View, CA) are under development but available data are insuffi cient for meaningful evaluation of safety and effi cacy. 26, 27 Inclusion and exclusion criteria for BET strategies are similar to those used for LVRS ( Table 2 ) . EBV targeted PULD and PLLD, IBV was used only for PULD, and BioLVR was tested both in heterogenous and homogenous distribution of the disease, whereas the pivotal ABT trial enrolled only the homogenous phenotype of emphysema ( Table 4 ) .
Zephyr EBV
Zephyr EBV is a self-expanding nitinol stent with a silicon one-way duckbill valve that allows egress of gas and mucus during exhalation but bars entry of air during inhalation. EBV is available in sizes to fi t subsegmental, segmental, and lobar bronchi. Valves can be removed or repositioned bronchoscopically. 22 During a nonrandomized 98-patient nine-center experience, a total of 396 EBV valves (4.04 6 1.6 valves per patient) were deployed with a 90-day follow-up. 28 Improvements in FEV 1 , FVC, residual volume (RV), and 6-min walk distance (6MWD) ( Table 4 ) were signifi cant without meeting Minimal Clinically Important Difference (MCID) levels. 36 Lobar targeting and the resultant lobar exclusion/ collapse (LE) produced better results than sublobar treatment ( Table 5 ) . Data on QOL instruments were not reported. It is diffi cult to interpret these outcomes because of the short follow-up period and lack of uniform treatment strategies, such as unilateral vs bilateral treatment, complete vs partial lobar exclusion, and so forth.
There were eight (8%) serious complications, including one death. The less serious adverse events consisted of 17 COPD exacerbations, fi ve pneumonias in nontreated lobes, and nine pneumothoraces b. Intrabronchial Valve (IBV) (Spiration Inc; Redmond, WA) 23 (Fig 2) 2. Biologic Lung Volume Reduction (BioLVR) (Aeris Therapeutics, Inc; Woburn, MA) involves deployment of a biodegradable gel into subsegmental bronchi to collapse targeted hyperinfl ated pulmonary parenchyma and initiate an infl ammatory response to selectively scar, shrink, and reduce the volume of treated lung. 24 
Airway Bypass Tracts (ABT) (Broncus Inc; Moun-
tain View, CA) achieved by creating extra anatomic fenestrations between hyperinfl ated pulmonary parenchyma and bronchial tree in order to allow escape of trapped gas and reduce lung volume. 25 None of the above four devices is approved by the FDA for treatment of emphysema in the United States; however, IBV and EBV received CE (Conformité Européenne) designation. Bronchoscopic Ther- outcomes from VENT were less favorable than from the 98-patient EBV cohort study. 38 Within 1 year of treatment, valve-related complications included device malfunction (9.8%), pneumonia distal to the valve (4.2%), valve expectoration/ migration (7.5%), and granulation tissue on the prosthesis (7%). CT scans after EBV deployment were available in 194 patients and showed satisfactory valve position in 109 (56.2%) patients but 85 (43.8%) exhibited malposition, expectoration, or other complications, of at least one valve. Moreover, only eight (28.6%) of the 28 participating clinical sites deployed all valves correctly, whereas 20 sites (71.4%) experienced varying degrees of technical failures. 39 A US Food and Drug Administration (FDA) panel convened on December 5, 2008, found Zephyr EBV "not approvable" but suggested further studies. 29 Subsequently Emphasys EBV was sold to Pulmonx Interventional Pulmonology, Palo Alto, CA. In an attempt to improve results Pulmonx introduced an endobronchial catheter-based device (Chartis System) for estimating collateral resistance and assist in selection of suitable patients for lung volume reduction. 40, 41 mostly associated with lobar collapse. In the ensuing EBV pivotal trial only one lung was targeted in order to prevent simultaneous collapse of both lungs.
The Endobronchial Valve for Emphysema Palliation Trial (VENT), a pivotal multicenter RCT (2:1 ratio of treated to control) with the Zephyr EBV valve, was completed in 2007 on 321 patients with heterogeneous emphysema. Upper or lower lobar, segmental, and subsegmental bronchi were unilaterally targeted. 37 Primary end points were changes in FEV 1 and 6MWD. In 214 treated patients, a total of 820 valves were inserted (median 4, range 1-9 per patient). During the procedure one or more valves were replaced or repositioned in 96 patients (45%) mostly because of unsatisfactory valve size or position. After correction of perceived shortcomings, the desired valve position was achieved in 95% of patients.
At the 6-and 12-month follow-ups, the treated cohort showed statistically signifi cant improvement in FEV 1 , 6MWD, and St. George Respiratory Questionnaire (SGRQ) compared with control subjects but failed to meet MCID criteria ( Table 4 ). The functional Spiration is presently conducting a double-blind, multicenter, randomized pivotal trial between bilateral IBV plus medical treatment and medical treatment alone on patients with PULD. Control subjects receive sham bronchoscopy. Primary effi cacy end points are changes in SGRQ and lung volume on CT scan.
BioLVR
BioLVR involves deployment of a biodegradable gel into subsegmental bronchi in order to collapse targeted hyperinfl ated pulmonary parenchyma and stimulate an infl ammatory response that scars and shrinks the treated lung. The biologic complex incorporates chondroitin sulfate and poly-l -lysine and is delivered in a fi brin vehicle simultaneously with a thrombin solution via a dual lumen catheter in the working channel of a fl exible bronchoscope. The contents of the two lumens meet, mix, and polymerize at the target airway site and form the BioLVR gel. The liquid component of the gel presumably fi lls alveoli and blocks collateral ventilation. Safety and effi cacy were demonstrated in a sheep emphysema model. 24 During a phase 2 non-RCT with PULD emphysema, 22 patients were treated with high-dose (HD 5 20 mL/subsegment) and 28 with low-dose (LD 5 10 mL/subsegment) BioLVR. The 6-month follow-up of 44 patients revealed greater improvement of FEV 1 , FVC, and RV in the HD than in the LD cohorts. There was no signifi cant change in 6MWD in either group ( Table 4 ) . At 6 weeks, CT scans showed localized scarring of treated sites in
IBV
The IBV is an umbrella-shaped, self-expanding device based on a similar unidirectional principle as its EBV counterpart ( Fig 2 ) . The valve is available in different sizes. Replacement or repositioning can be accomplished bronchoscopically. 30, 31 During a multicenter, nonrandomized, bilateral treatment trial on heterogeneous emphysema, a total of 609 valves (mean 6.7 valves per patient) were implanted in 91 patients. Segmental or subsegmental airways were targeted in 74% and 26%, respectively. 30, 42 Technical diffi culties with valve implantation were encountered in two and pneumothorax occurred in nine patients, with one fatality. There was one nonfatal myocardial infarction and seven patients experienced bronchospasm. Migration, erosion, or expectoration of the valve and severe hemoptysis were not reported. Fortyfour valves from 16 patients were removed for pneumonia, bronchospasm, COPD exacerbation, and pneumothorax.
At 6 and 12 months post-IBV implant, SGRQ improved but spirometry, lung volumes, and 6MWD did not change signifi cantly ( Table 4 ) . No valve migration or expectoration was observed. CT scans showed no change in total lung capacity (TLC) but the volume of the targeted lobe decreased by approximately 10% in 87% of the subjects, whereas the volume of the nontreated territory increased by 11.0% in about 94% of the patients. The shifts in lobar volumes correlated with improvement in SGRQ ( P , .01) and lung perfusion scans showed a shift of perfusion from the treated upper lobe to the nontreated lower lobe. a new product (Polymeric Lung Volume Reduction) were initiated.
Interlobar Fissure, Targeting Strategy, and Effectiveness of BET One year after EBV treatment in the VENT trial 33 of 151 subjects (21.9%) with available CT scans showed complete interlobar fissures and lobar exclusion/collapse (CFLE). These patients exhibited both improved spirometry and SGRQ. The 118 of 151 patients (78.1%) without CFLE experienced only improvement in SGRQ without favorable change in spirometry ( Table 5 ) . 43 In an IBV study lobar collapse was also associated with better symptomatic and physiologic response than sublobar or no collapse ( Table 5 ) . 30 However, lobar collapse was associated with an increased incidence of treatable pneumothorax. With BioLVR, unilateral lobar treatment showed better results than bilateral targeting with the same or higher dosage at scattered subsegments ( Table 5 ) . 34 Thus, it appears that by preventing cross-lobar collateral ventilation, complete lobar fi ssure facilitates more durable lobar collapse and effective lung volume reduction by unidirectional valves or BioLVR durable lobar collapse and effective lung volume reduction. This observation suggests that selection of patients with complete interlobar fi ssures would improve results from LVR. However, more data are needed to establish the reliability of assessment of the state of lobar fi ssures by CT imaging. The Chartis System may aid in estimating the degree of collateral 57% 6 17% of LD and 68% 6 20% of patients treated with HD BioLVR. The scarring at 6 months was sustained in the HD but not in the LD cohort. Radiologic evidence of scarring correlated with improvement in FEV 1 . 32 In a study on bilateral treatment of homogenous emphysema, 17 patients received HD-BioLVR and eight patients received LD-BioLVR. At the 6-month follow-up, FEV 1 , FVC, and RV/TLC improved in HD-BioLVR but not in the LD-BioLVR group. SGRQ improved in both arms of the study, but 6MWD improved in neither ( Table 4 ) . 33 In another HD BioLVR study on PULD, nine patients were treated at four subsegments in each of two upper lobes (bilateral-scattered), and 12 patients were treated at fi ve to eight subsegments in one upper lobe (lobar-contiguous). Targeting a single lobe produced better results than an equal or larger dose delivered bilaterally into scattered subsegments of two lobes ( Table 4 ) . 34 BioLVR treatment was followed within 24 h, in . 90% of patients, by a syndrome of fever, pleuritic pain, nausea, headache, malaise, and leukocytosis, consistent with an anticipated infl ammatory response to the biologic materials introduced into the airways. The reaction subsided within 24 to 48 h. No deaths or device-related complications were reported. On November 8, 2008, Aeris notifi ed participating clinical sites that the company failed to come to an agreement with FDA on a phase 3 study design and that further testing was deferred. Subsequently the work on BioLVR was halted and feasibility studies on procedure the primary FEV 1 end point was not met but improvement in modified Medical Research Council score was statistically significant. At the 1-month follow-up, RV decreased by . 500 mL in approximately 40% of EBV-treated patients. However, characteristics of this favorable patient group and the duration of the improvement were not reported. 47 
Comments
A review of the published results from lung volume therapies for emphysema supports the following conclusions: First, observational and randomized studies provide compelling evidence that LVRS improves pulmonary function, exercise capacity, health-related QOL, and survival, especially in the PULD-low baseline exercise tolerance subset. The reasons for the apparent underuse of the procedure are not clear.
Second, the four extensively tested BET approaches are safer but far less effective than LVRS. Available data indicate IBV and BioLVR improve SGRQ values by MCID levels ( . 4 units) and surpass the mean change of 3.5 SGRQ units reported from the large pharmaceutical trials with salmeterol/fluticasone in Towards a Revolution in COPD Health Study (TORCH) and tiotropium in Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT). 48, 49 IBV is also associated with decreased volumes in the treated and an increase in untreated regions of the lung on CT scan. These volume shifts correlate with improvement in SGRQ but without concomitant changes in lung function or exercise tolerance suggesting redirection of ventilation from treated to untreated areas. EBV and ABT did not meet primary end points on pivotal trials. ABT was followed by symptomatic and physiologic improvements in 40% of patients 1 month after treatment but the observed 31% stent closure at 6 months will probably prevent a sustained response. Based on pilot studies, BioLVR is associated with symptomatic and physiologic benefi ts. Although the physiologic changes do not reach MCID values, BioLVR has the promise of an effective bronchoscopic approach but further work was halted by the sponsor so that pivotal studies to verify the results probably will not be conducted. The physiologic improvements observed from the various bronchoscopic strategies to volume reduction do not reach MCID levels and longer-term follow-ups have not been reported. Although it is maintained that experienced bronchoscopists could perform the procedures without an intensive training, the frequent technical failures during deployment of EBV cast doubts on this claim. Third, a complete interlobar fi ssure facilitates lobar exclusion/collapse and may be instrumental in improved QOL and lung ventilation to regions of the lung under consideration for treatment with airway obstructive devices. 41, 42 ABT Choong and colleagues 25 hypothesized that creation of nonanatomic airways between hyperinfl ated pulmonary parenchyma and adjacent bronchi (ABT) would decompress hyperinfl ated lung and reduce its volume. The procedure is designed for homogenous emphysema and performed with a fl exible fi beroptic bronchoscope as follows: (1) identifi cation of blood vessels adjacent to planned sites of bronchial fenestration with a Mini Doppler Probe (Yield) in order to avoid vascular injury and bleeding, (2) fenestration of extraanatomic channels between bronchus and hyperinfl ated air spaces with a proprietary needleballoon catheter (Yield), and (3) insertion of a paclitaxeleluting stent (Exhale) to dilate the newly created channel and to maintain patency.
In 12 human lungs, explanted during lung transplantation for COPD, creation of three ABT channels increased FEV 1 from 245 6 107 mL to 447 6 199 mL ( P , .001) and the addition of two more fenestrations to 666 6 284 mL. ( P 5 .001). 44 Animal studies 12 weeks after creation of stented ABT demonstrated patency rates of paclitaxel-eluting vs bare metal stents of 65% vs 0%. 45 In a 35-patient multicenter ABT pilot study on severe homogenous emphysema, a median of eight (range 2-12 per patient) stented fenestrations were created bilaterally, in upper and lower lobes. 35 A baseline RV/TLC . 0.67 was associated with improved FVC, TLC, RV, and SGRQ, but patients with RV/ TLC Յ 0.67 did not improve ( Table 4 ). 6MWD and FEV 1 remained unchanged in both groups ( Table 4 ) . Bleeding during the procedure was controlled with topical epinephrine in all cases except for one patient who exsanguinated. Other complications included 12 COPD exacerbations, 10 respiratory infections, and two cases of pneumomediastinum. Six months after insertion 18 of 26 (69%) stents examined bronchoscopically were patent. Grgic and colleagues 46 reported that patency of the stents can be detected by multidetector CT scanning with a 94.7% sensitivity and 100% specifi city.
Exhale Airway Stents for Emphysema is an FDAapproved double-blind multicenter pivotal trial on homogeneous emphysema and an RV/TLC of Ն 0.65. Patients were randomized between ABT and sham bronchoscopy control in a ratio of 2:1. The primary end points are Ն 12% improvement in FVC and Ն 1-point reduction in modifi ed Medical Research Council scale score. The study enrolled 315 patients. Preliminary reports indicate that 6 months after the only 511, or 12.7% of the 3,997 screened patients, had the favorable PULD distribution. Our retrospective analysis of 959 patients whose PFTs refl ected Global Initiative for Chronic Obstructive Lung Disease stage 3 and 4 severity included 413 individuals a primary clinical diagnosis of emphysema and available CT scans. On the basis of current inclusion/ exclusion criteria 15% of the 413 could be candidates for LVRS. 52 This estimate is consistent with other reported data on the issue and appears to refl ect a realistic projection of the size of population that could benefi t from lung volume reduction.
In conclusion, the LVRS experience demonstrates convincingly that the principle of lung volume reduction is sound and the surgery is effective but associated with substantial mortality and morbidity. The ongoing search for a safe and effective BET has made signifi cant strides and yielded partial success in some aspects. Although some presently available BLT devices are approved for use by European regulatory authorities, the available information does not warrant a recommendation for routine clinical use. Emerging bronchoscopic therapies for LVR may not quantitatively match the response obtained from LVRS, but even modest improvement over medical therapy, as assessed through an evidence-based, standardized, and multidimensional approach, would function by both unidirectional valves and BioLVR ( Table 5 ) .
Fourth, midterm (1-3 years) durability and complications from the various BET strategies are not known. The relatively low complication rates combined with improvement in SGRQ and favorable lung volume shifts on CT scan suggest that IBV and EBV posses therapeutic potential. Predictors associated with symptomatic and physiologic improvements from ABT treatment have not been identifi ed. In view of an anticipated relatively high stent closure rate, the duration of the improvement beyond 1 month remains to be seen.
The goal of any medical treatment is either to extend life span or to improve its quality, and ideally both. This principle is a basic tenet of medical therapeutics and forms the backbone of medical practice. Replacement of joints is a prime example of improving QOL without adding to longevity. Similarly, the majority of cardiac revascularization procedures palliate but do not extend survival. Palliation without lengthening life span is especially rewarding in debilitating diseases. The recent search for interventional treatment of advanced emphysema may have placed an undue emphasis on survival benefi ts without sufficient regard for the value of palliation. It would seem that a treatment modality with an acceptable low risk that provides palliation for at least 12 months could be viewed as therapeutic even without improvement in physiologic parameters.
Contrary to projections, it is apparent that the various BET approaches will cost more than originally estimated. Preliminary information indicates that most BET systems will cost $12,000 to $20,000 per procedure.
The continued search for safe and effective minimally invasive approaches to LVT will likely produce promising new methods. At present, however, no uniform system is available for assessing therapeutic merits of emerging strategies. A classifi cation based on universally recognized variables would facilitate evidence-based evaluation of the clinical value of emerging BETs. The safety of a new device under consideration combined with the proposed effi cacy grading can provide evidence-based risk/benefi t information on clinical value ( Table 6 ) .
Sound health-care planning requires evidencebased estimates on use of emerging therapies. The number of patients who might benefi t from LVRS or BET is highly controversial. Estimates range from the 254 operations performed between 2004 and 2005 to the projection by Make and Fein 50 that 1.35 million patients could benefi t from LVRS. Weinstein reported that only 10% of patients referred to a tertiary care center for LVRS had the operation. 51 NETT evaluated 3,997 patients, enrolled 1,218, and represent an advance in the treatment of severe emphysema.
